The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Abstract
Purpose: To further understand the molecular pathogenesis of pulmonary sarcomatoid carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory disease. Materials and Methods: Whole-exome sequencing in a discovery set (n = 10) as well as targeted MET mutation screening in an independent validation set (n = 26) of PSC were performed. Reverse transcriptase polymerase chain reaction and Western blotting were performed to validate MET exon 14 skipping. Functional studies for validation of the oncogenic roles of MET exon 14 skipping were conducted in lung adenosquamous cell line H596 (MET exon 14 skipped and PIK3CA mutated) and gastric adenocarcinoma cell line Hs746T (MET exon 14 skipped). Response to MET inhibitor therapy with crizotinib in a patient with advanced PSC and MET exon 14 skipping was evaluated to assess clinical translatability. Results: In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated. MET mutations leading to exon 14 skipping were identified in eight (22%) of 36 patient cases; one of these tumors also harbored a concurrent PIK3CA mutation. Short interfering RNA silencing of MET and MET inhibition with crizotinib showed marked effects on cell viability and decrease in downstream AKT and mitogen-activated protein kinase activation in Hs746T and H596 cells. Concurrent PIK3CA mutation required addition of a second agent for successful pathway suppression and cell viability effect. Dramatic response to crizotinib was noted in a patient with advanced chemotherapy-refractory PSC carrying a MET exon 14 skipping mutation. Conclusion: Mutational events of MET leading to exon 14 skipping are frequent and potentially targetable events in PSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Predicting the Functional Effect of Amino Acid Substitutions and Indels
Choi, Y., Sims, G. E., Murphy, S., Miller, J. R., & Chan, A. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046688 · Cited by 2,890
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“A2888del Somatic Yes Yes No No 5 Intron 13 (1-28) deletion Somatic Yes No No No 5 c.”
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility
Stoker, M., Gherardi, E., Perryman, M., & Gray, J. (1987) · Nature · doi:10.1038/327239a0 · Cited by 1,314
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Self-citationLinardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Evidence for the identity of human scatter factor and human hepatocyte growth factor.
Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., & Daikuhara, Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.7001 · Cited by 652
The transcriptional landscape and mutational profile of lung adenocarcinoma
Seo, J.-S., Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, J. K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J.-O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 584
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 516
Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2749 · Cited by 490
Onozato, R., Kosaka, T., Kuwano, H., Sekido, Y., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913e0e · Cited by 327
Camidge, D. R., Ou, S.-H. I., Shapiro, G., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella-Garcia, M., Dacic, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma
Vieira, T., Girard, N., Ung, M., Monnet, I., Cazes, A., Bonnette, P., Duruisseaux, M., Mazieres, J., Antoine, M., Cadranel, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000437008.00554.90 · Cited by 208
Chaft, J. E., Arcila, M. E., Paik, P. K., Lau, C., Riely, G. J., Pietanza, M. C., Zakowski, M. F., Rusch, V., Sima, C. S., Ladanyi, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0692 · Cited by 202
Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
Okuda, K., Sasaki, H., Yukiue, H., Yano, M., & Fujii, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00916.x · Cited by 198
Spoerke, J. M., O'Brien, C., Huw, L., Koeppen, H., Fridlyand, J., Brachmann, R. K., Haverty, P. M., Pandita, A., Mohan, S., Sampath, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2347 · Cited by 182
CRAVAT: cancer-related analysis of variants toolkit
Douville, C. B., Carter, H. K., Kim, R., Niknafs, N., Diekhans, M., Stenson, P. D., Cooper, D. N., Ryan, M., & Karchin, R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt017 · Cited by 171
Wang, L., Hu, H., Pan, Y., Wang, R., Li, Y., Shen, L., Yu, Y., Li, H., Cai, D., Sun, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088291 · Cited by 164
Dhanasekaran, S. M., Balbin, O. A., Chen, G., Nadal, E., Sundaram, S. K., Pan, J., Veeneman, B. A., Cao, X., Malik, R., Vats, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6893 · Cited by 160
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Martin, L. W., Correa, A. M., Ordóǹez, N. G., Roth, J. A., Swisher, S. G., Vaporciyan, A. A., Walsh, G. L., & Rice, D. C. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.03.099 · Cited by 146
CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer
Wong, W. C., Kim, D., Carter, H. K., Diekhans, M., Ryan, M., & Karchin, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr357 · Cited by 142
Pulmonary Pleomorphic Carcinoma: A Clinicopathological Study Including EGFR Mutation Analysis
Kaira, K., Horie, Y., Ayabe, E., Murakami, H., Takahashi, T., Tsuya, A., Nakamura, Y., Naito, T., Endo, M., Kondo, H., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ce3e3c · Cited by 133
Ichihara, S., Toyooka, S., Fujiwara, Y., Hotta, K., Shigematsu, H., Tokumo, M., Soh, J., Asano, H., Ichimura, K., Aoe, K., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22513 · Cited by 129
Italiano, A., Cortot, A. B., Ilié, M., Martel‐Planche, G., Fabas, T., Pop, D., Mouroux, J., Hofman, V., Hofman, P. M., & Pédeutour, F. (2009) · International Journal of Cancer · doi:10.1002/ijc.24610 · Cited by 114
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Jenkins, R. W., Oxnard, G. R., Elkin, S. K., Sullivan, E. K., Carter, J. L., & Barbie, D. A. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.009 · Cited by 104
Vieira, T., Antoine, M., Ruppert, A.-M., Fallet, V., Duruisseaux, M., Leprieur, E. G., Poulot, V., Rabbe, N., Sclick, L., Beau‐Faller, M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.004 · Cited by 88
Pelosi, G., Gasparini, P., Cavazza, A., Rossi, G., Graziano, P., Barbareschi, M., Perrone, F., Barberis, M. C. P., Takagi, M., Kunimura, T., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.093 · Cited by 77
Asaoka, Y., Tada, M., Ikenoue, T., Seto, M., Imai, M., Miyabayashi, K., Yamamoto, K., Yamamoto, S., Kudo, Y., Mohri, D., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.120 · Cited by 76
Met degradation: more than one stone to shoot a receptor down
Lefebvre, J., Ancot, F., Leroy, C., Muharram, G., Lemière, A., & Tulasne, D. (2012) · The FASEB Journal · doi:10.1096/fj.11-197723 · Cited by 74
Ushiki, A., Koizumi, T., Kobayashi, N., Kanda, S., Yasuo, M., Yamamoto, H., Kubo, K., Aoyagi, D., & Nakayama, J. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn155 · Cited by 72
Chang, Y., Wu, C., Shih, J., & Lee, Y.-C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1621-7 · Cited by 66
Identification of EGFR mutations in lung sarcomatoid carcinoma
Leone, A., Graziano, P., Gasbarra, R., Paone, G., Cardillo, G., Mancuso, A. P., de Marinis, F., Ricciardi, S., Portalone, L., & Pisa, R. (2010) · International Journal of Cancer · doi:10.1002/ijc.25335 · Cited by 41
Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma
Peng, H., Wen, J., Li, H., Chang, J., & Zhou, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014750 · Cited by 31
Cited by
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Jänne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 693
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 645
Tong, J. H., Yeung, S. F., Chan, A. W. H., Chung, L. Y., Chau, S. L., Lung, R. W. M., Tong, C. Y., Chow, C., Tin, E. K. Y., Yu, Y. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2061 · Cited by 449
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0716-8 · Cited by 395
Metadata
- Authors
- Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., Mansukhani, M., Koul, S., Halmos, B., & Borczuk, A. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-03-10
- Volume
- 34
- Issue
- 8
- Pages
- 794-802
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159426719
- Cited by
- 349
- References
- 36
- FWCI
- 30.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.